News | February 25, 2026
Formosa strikes exclusive deal with Arrotex to launch eye surgery drug in Australia & NZ
The innovative eyedrop targets inflammation and pain following ocular surgery
The innovative eyedrop targets inflammation and pain following ocular surgery
Nadda underlined that India’s policy framework is aligned with this transformation
The product will target Type 2 diabetes management aligning with unmet needs in India’s expanding metabolic care landscape
One of India’s top integrated contract research, development, and manufacturing organizations (CRDMOs) is on a hiring spree
To support this launch, ImmunityBio has established a wholly owned subsidiary in Saudi Arabia
The project entails a total planned capital expenditure of approximately Rs. 500 - 520 crore
The alliance directly links VivaMed’s computational drug hypotheses with Syngene’s preclinical development capabilities
This multi-year CDMO agreement involves significant, ongoing manufacturing for a global pharmaceutical major
Our vision is to position India not just as a consumer of advanced simulation technologies but as a creator and exporter of them
Expansion at the Oss (NL) site adds capacity and R&D capabilities, supporting the development and manufacturing of ADCs and other novel bioconjugates from First-in-Human to commercialization
Subscribe To Our Newsletter & Stay Updated
